Logo

The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

Share this
RemeGen

The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

Shots:

  • Following the IND approval in the Dec’23, the company’s RC88 has received FTD from the US FDA for treating Pt-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
  • The company’s RC88 is being evaluated as monotx. for its optimal dosage, effectiveness, and safety in P-II trial to treat Pt-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
  • RC88, recombinant humanized anti-MSLN mAb associated with the microtubule inhibitor monomethyl auristatin E (MMAE), binds to tissues overexpressing MSLN, demonstrating a terminating effect on tumor cells with varying MSLN expression levels

Ref: PRNewswire | Image: RemeGen

Related News:- RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for Advanced Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions